UroGen Pharma to Participate in the B. Riley Healthcare Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/21/2026

1. ROST
2. WMT
3. AAP
4. SPY
5. HD

6. SFNC
7. FMG:AU
8. AVAH
9. JHX
10. FSUGY

Get Alerts URGN Hot Sheet

Price: $46.80 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

- Fireside Chat January 18, 2024, at 12:00 pm ET -

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Liz Barrett, President and CEO, will participate in a fireside chat at the upcoming B. Riley Virtual Healthcare Conference on January 18th beginning at 12:00 p.m. ET.

To access the event, please RSVP to your B. Riley Securities sales representative. Following the event, a replay of the fireside chat will be available at the "Events and Presentations" section of UroGen’s investor website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.